In a clinical study of 25 patients who had various malignancies containing NTRK, ROS1, or ALK gene fuses and received an effective dose of entrectinib, an overall response rate of 79% with significant tumor regression in all NTRK-altered tumors (including ETv6: NTRK3 translocation) [29] was observed. The gene discussed is NTRK3; the disease is neoplasm.